AboutBusiness
HelpPrivacyTerms
RiepilogoLegale e statoCronologiaReteProprietà e organiSociBeneficiario effettivoGeografiaBilancioSalute finanziariaDocumenti
RiepilogoLegale e statoCronologiaReteProprietà e organiSociBeneficiario effettivoGeografiaBilancioSalute finanziariaDocumenti

PERFORMANCE PHARMATECH LTD.

Private Limited Company (Ltd.)•Active

Riepilogo

Country🇬🇧Regno Unito
StatusActive
Registration Number06775451
Founded17/12/2008
PurposeOther human health activities
Address10 Wellington Street, Cambridge, Cambridgeshire, CB1 1HW
Confirmation StatementNext due: 30/12/2026; Last made up: —

Dati legali e stato

Legal FormPrivate Limited Company (Ltd.)
StatusActive
Registration Date17/12/2008
Registry Authority—

Source: — · Last updated: 02/12/2025

Timeline (32 events)

05/02/2026

Annual accounts filed

Micro company accounts made up to 31 December 2025

View file in Documents

15/12/2025

Appointed Judith Osborne (person)

Appointed as Director

17/12/2008

Appointed Paul Michael Osborne (person)

Appointed as Director

Rete

Questo grafico ha molte connessioni. per una vista migliore.
Press enter or space to select a node. You can then use the arrow keys to move the node around. Press delete to remove it and escape to cancel.
Press enter or space to select an edge. You can then press delete to remove it or escape to cancel.
Profondità rete

Proprietà e organi

Persons with significant control

Paul Michael Osborne

25–50% shares

Appointed: 06/04/2016

37.5%
Paul Michael Osborne

25–50% shares

Appointed: 06/04/2016

37.5%
Judith Osborne

25–50% shares

Appointed: 06/04/2016

37.5%
Judith Osborne

25–50% shares

Appointed: 06/04/2016 · Resigned: 14/12/2025

37.5%

Officers & directors

Judith Osborne

Director

Appointed: 15/12/2025

—

Showing 1–5 of 8

1 / 2

Ownership Timeline (4 changes)

15/12/2025

Appointed Judith Osborne (person)

Person with significant control

14/12/2025

Resigned Judith Osborne (person)

Person with significant control

06/04/2016

Appointed Paul Michael Osborne (person)

Person with significant control

Soci (azionariato)

NomePartecipazioneVotoDal
▓▓▓▓▓▓▓▓▓▓▓▓
█.██%
██%
█.█%
▓▓▓▓▓▓▓▓▓▓▓
██%
█.█%
██.██%
▓▓▓▓▓▓▓▓▓▓▓▓▓
█.█%
██.██%
██.█%
▓▓▓▓▓▓▓▓▓▓
██.██%
██.█%
█.██%
▓▓▓▓▓▓▓▓▓▓▓▓
██.█%
█.██%
██%
▓▓▓▓▓▓▓▓▓▓▓
█.██%
██%
█.█%
▓▓▓▓▓▓▓▓▓▓▓▓▓
██%
█.█%
██.██%
▓▓▓▓▓▓▓▓▓▓
█.█%
██.██%
██.█%

Beneficiario effettivo

NomePartecipazionePaeseDal
▓▓▓▓▓▓▓▓▓▓▓▓
█.██%
██%
█.█%
▓▓▓▓▓▓▓▓▓▓▓
██%
█.█%
██.██%
▓▓▓▓▓▓▓▓▓▓▓▓▓
█.█%
██.██%
██.█%
▓▓▓▓▓▓▓▓▓▓
██.██%
██.█%
█.██%
▓▓▓▓▓▓▓▓▓▓▓▓
██.█%
█.██%
██%
▓▓▓▓▓▓▓▓▓▓▓
█.██%
██%
█.█%
▓▓▓▓▓▓▓▓▓▓▓▓▓
██%
█.█%
██.██%
▓▓▓▓▓▓▓▓▓▓
█.█%
██.██%
██.█%

Geografia

Sede

10 Wellington Street

Cambridge

Cambridgeshire

CB1 1HW

Bilancio e conti

Cifre chiave dai bilanci depositati.

Convert to

2013

Profit / (loss): £56.5K

Key figures

Profit / (loss)

2013£56.477
2014£102.148
2015£230.332
2016—
2017—
2018—
2019—
2020—
2021—
2022—
2023—
2024—

Total assets

2013£56.479
2014£102.150
2015£230.334
2016£371.205
2017£486.498
2018£319.822
2019£322.320
2020£218.810
2021£212.958
2022£239.537
2023£118.827
2024£85.470

Net Assets Liabilities

2013—
2014—
2015—
2016£371.205
2017£486.498
2018£319.822
2019£322.320
2020£218.810
2021£212.958
2022£239.537
2023£118.827
2024£85.470

Equity

2013—
2014—
2015—
2016£371.205
2017£486.498
2018£319.822
2019£322.320
2020£218.810
2021£212.958
2022£239.537
2023£118.827
2024£85.470

Current Assets

2013£72.631
2014£137.618
2015£292.050
2016£418.708
2017£586.167
2018£343.787
2019£381.992
2020£226.016
2021£227.038
2022£265.063
2023£124.656
2024£94.000

Net Current Assets Liabilities

2013£55.273
2014£99.556
2015£224.338
2016£364.941
2017£495.531
2018£316.390
2019£320.880
2020£218.412
2021£212.272
2022£239.579
2023£118.709
2024£85.192

Total Assets Less Current Liabilities

2013—
2014—
2015—
2016£371.906
2017£502.807
2018£320.397
2019£322.895
2020£219.385
2021£213.533
2022£240.112
2023£119.402
2024£86.327

Debtors

2013£28.594
2014£56.721
2015£119.644
2016—
2017—
2018—
2019—
2020—
2021—
2022—
2023—
2024—

Creditors

2013—
2014—
2015—
2016£54.740
2017£91.480
2018£29.313
2019£62.070
2020£8298
2021£15.387
2022£26.012
2023£6676
2024£9221

Number Shares Allotted

20132
20142
20152
2016—
2017—
2018—
2019—
2020—
2021—
2022—
2023—
2024—

Par Value Share

2013£1
2014£1
2015£1
2016—
2017—
2018—
2019—
2020—
2021—
2022—
2023—
2024—

Average Number Employees During Period

2013—
2014—
2015—
2016—
2017—
2018—
2019—
20202
20212
20222
20232
20242

Accrued Liabilities Not Expressed Within Creditors Subtotal

2013—
2014—
2015—
2016£701
2017£16.309
2018£575
2019£575
2020£575
2021£575
2022£575
2023£575
2024£857

Called Up Share Capital

2013£2
2014£2
2015£2
2016—
2017—
2018—
2019—
2020—
2021—
2022—
2023—
2024—

Capital Employed

2013£56.479
2014£102.150
2015£230.334
2016—
2017—
2018—
2019—
2020—
2021—
2022—
2023—
2024—

Cash Bank In Hand

2013£44.037
2014£40.897
2015£72.406
2016—
2017—
2018—
2019—
2020—
2021—
2022—
2023—
2024—

Creditors Due Within One Year

2013£17.358
2014£38.062
2015£67.712
2016—
2017—
2018—
2019—
2020—
2021—
2022—
2023—
2024—

Current Asset Investments

2013£40.000
2014£40.000
2015£100.000
2016—
2017—
2018—
2019—
2020—
2021—
2022—
2023—
2024—

Fixed Assets

2013—
2014—
2015—
2016£6965
2017£7276
2018£4007
2019£2015
2020£973
2021£1261
2022£533
2023£693
2024£1135

Net Assets Liabilities Including Pension Asset Liability

2013£56.479
2014£102.150
2015£230.334
2016—
2017—
2018—
2019—
2020—
2021—
2022—
2023—
2024—

Prepayments Accrued Income Not Expressed Within Current Asset Subtotal

2013—
2014—
2015—
2016£973
2017£844
2018£1916
2019£958
2020£694
2021£621
2022£528
2023£729
2024£413

Profit Loss Account Reserve

2013£56.477
2014£102.148
2015£230.332
2016—
2017—
2018—
2019—
2020—
2021—
2022—
2023—
2024—

Share Capital Allotted Called Up Paid

2013£2
2014£2
2015£2
2016—
2017—
2018—
2019—
2020—
2021—
2022—
2023—
2024—

Tangible Fixed Assets

2013£1206
2014£2594
2015£5996
2016—
2017—
2018—
2019—
2020—
2021—
2022—
2023—
2024—

Tangible Fixed Assets Additions

2013£3206
2014£6922
2015£6132
2016—
2017—
2018—
2019—
2020—
2021—
2022—
2023—
2024—

Tangible Fixed Assets Cost Or Valuation

2013£5953
2014£11.308
2015£16.406
2016—
2017—
2018—
2019—
2020—
2021—
2022—
2023—
2024—

Tangible Fixed Assets Depreciation

2013£3359
2014£5312
2015£9441
2016—
2017—
2018—
2019—
2020—
2021—
2022—
2023—
2024—

Tangible Fixed Assets Depreciation Charged In Period

2013£1818
2014£3178
2015£5163
2016—
2017—
2018—
2019—
2020—
2021—
2022—
2023—
2024—

Tangible Fixed Assets Depreciation Decrease Increase On Disposals

2013£966
2014£1225
2015£1034
2016—
2017—
2018—
2019—
2020—
2021—
2022—
2023—
2024—

Tangible Fixed Assets Disposals

2013£966
2014£1567
2015£1034
2016—
2017—
2018—
2019—
2020—
2021—
2022—
2023—
2024—
Metric201320142015201620172018201920202021202220232024
Profit / (loss)£56.477£102.148£230.332—————————
Total assets£56.479£102.150£230.334£371.205£486.498£319.822£322.320£218.810£212.958£239.537£118.827£85.470
Net Assets Liabilities———£371.205£486.498£319.822£322.320£218.810£212.958£239.537£118.827£85.470
Equity———£371.205£486.498£319.822£322.320£218.810£212.958£239.537£118.827£85.470
Current Assets£72.631£137.618£292.050£418.708£586.167£343.787£381.992£226.016£227.038£265.063£124.656£94.000
Net Current Assets Liabilities£55.273£99.556£224.338£364.941£495.531£316.390£320.880£218.412£212.272£239.579£118.709£85.192
Total Assets Less Current Liabilities———£371.906£502.807£320.397£322.895£219.385£213.533£240.112£119.402£86.327
Debtors£28.594£56.721£119.644—————————
Creditors———£54.740£91.480£29.313£62.070£8298£15.387£26.012£6676£9221
Number Shares Allotted222—————————
Par Value Share£1£1£1—————————
Average Number Employees During Period———————22222
Accrued Liabilities Not Expressed Within Creditors Subtotal———£701£16.309£575£575£575£575£575£575£857
Called Up Share Capital£2£2£2—————————
Capital Employed£56.479£102.150£230.334—————————
Cash Bank In Hand£44.037£40.897£72.406—————————
Creditors Due Within One Year£17.358£38.062£67.712—————————
Current Asset Investments£40.000£40.000£100.000—————————
Fixed Assets———£6965£7276£4007£2015£973£1261£533£693£1135
Net Assets Liabilities Including Pension Asset Liability£56.479£102.150£230.334—————————
Prepayments Accrued Income Not Expressed Within Current Asset Subtotal———£973£844£1916£958£694£621£528£729£413
Profit Loss Account Reserve£56.477£102.148£230.332—————————
Share Capital Allotted Called Up Paid£2£2£2—————————
Tangible Fixed Assets£1206£2594£5996—————————
Tangible Fixed Assets Additions£3206£6922£6132—————————
Tangible Fixed Assets Cost Or Valuation£5953£11.308£16.406—————————
Tangible Fixed Assets Depreciation£3359£5312£9441—————————
Tangible Fixed Assets Depreciation Charged In Period£1818£3178£5163—————————
Tangible Fixed Assets Depreciation Decrease Increase On Disposals£966£1225£1034—————————
Tangible Fixed Assets Disposals£966£1567£1034—————————

Documenti

Micro company accounts made up to 31 December 2025

05/02/2026

View

Change of director details

02/02/2026

View

Change of details for person with significant control

30/01/2026

View

Change of director details

30/01/2026

View

Change of details for person with significant control

30/01/2026

View

Document AI

Coming soon

Companexia Document AI

Ask questions about filings and extracts—our AI will read the documents and answer in context.

Confirmation statement

30/01/2026

View

Cessation as person with significant control

30/01/2026

View

Change of director details

30/01/2026

View

Termination of director appointment

30/01/2026

View

Showing 1–10 of 51

1 / 6

Altre aziende e persone

🇮🇪KILDALE LIMITED🇮🇪BRAMBURY LIMITED🇮🇪CLOVERWOOD LIMITEDBRUNO MARCEL HOUCHEMARION SCHLEGELGRACE NEWTON I
Current ratio (2015)Current ratio
4,31×
YoY profit / (loss) (2014 vs 2015)YoY profit / (loss)
+125,5%
Return on assets (net) (2015)Return on assets (net)
100%
Equity ratio (2024)Equity ratio
100%
YoY total assets (2023 vs 2024)YoY total assets
-28,1%

Financial Health

Derived ratios from annual accounts. Values are omitted when data is missing or not meaningful.

Growth

YoY profit / (loss) (2013 vs 2014)
+80,9%
YoY total assets (2013 vs 2014)
+80,9%
YoY net current assets (2013 vs 2014)
+80,1%
YoY profit / (loss) (2014 vs 2015)
+125,5%
YoY total assets (2014 vs 2015)
+125,5%
  1. –Cambridge
  2. –PERFORMANCE PHARMATECH LTD.
YoY net current assets (2014 vs 2015)
+125,3%
YoY total assets (2015 vs 2016)
+61,2%
YoY net current assets (2015 vs 2016)
+62,7%
YoY total assets (2016 vs 2017)
+31,1%
YoY net current assets (2016 vs 2017)
+35,8%
YoY total assets (2017 vs 2018)
-34,3%
YoY net current assets (2017 vs 2018)
-36,2%
YoY total assets (2018 vs 2019)
+0,8%
YoY net current assets (2018 vs 2019)
+1,4%
YoY total assets (2019 vs 2020)
-32,1%
YoY net current assets (2019 vs 2020)
-31,9%
YoY total assets (2020 vs 2021)
-2,7%
YoY net current assets (2020 vs 2021)
-2,8%
YoY total assets (2021 vs 2022)
+12,5%
YoY net current assets (2021 vs 2022)
+12,9%
YoY total assets (2022 vs 2023)
-50,4%
YoY net current assets (2022 vs 2023)
-50,5%
YoY total assets (2023 vs 2024)
-28,1%
YoY net current assets (2023 vs 2024)
-28,2%
CAGR total assets (2013–2024)
+3,8%

Efficiency & returns

Return on assets (net) (2013)
100%
Return on assets (net) (2014)
100%
Return on assets (net) (2015)
100%

Working capital & liquidity

Current ratio (2013)
4,18×
Net current assets (2013)
55.273 £
Current ratio (2014)
3,62×
Net current assets (2014)
99.556 £
Current ratio (2015)
4,31×
Net current assets (2015)
224.338 £
Net current assets (2016)
364.941 £
Net current assets (2017)
495.531 £
Net current assets (2018)
316.390 £
Net current assets (2019)
320.880 £
Net current assets (2020)
218.412 £
Net current assets (2021)
212.272 £
Net current assets (2022)
239.579 £
Net current assets (2023)
118.709 £
Net current assets (2024)
85.192 £

Capital structure

Equity ratio (2016)
100%
Equity ratio (2017)
100%
Equity ratio (2018)
100%
Equity ratio (2019)
100%
Equity ratio (2020)
100%
Equity ratio (2021)
100%
Equity ratio (2022)
100%
Equity ratio (2023)
100%
Equity ratio (2024)
100%
Home